H.EncarnaoR.NorbergS.JonesR.ReinapM.et al (2014)
Patients who inject sermorelin in the morning report minimal subjective benefit and show lower serum IGF-1 increases (the downstream marker of GH bioactivity) compared to those injecting before bed
A sweeping review of dozens of clinical trials suggests that todays most widely used GLP-1 receptor agonist drugs produce broadly consistent weight-loss results across age, race, ethnicity, and baseline health measures
Produkty oferowane poza oficjalnym systemem medycznym mog nie mie potwierdzonego skadu ani jakoci, a ich stosowanie moe wiza si z ryzykiem dla zdrowia
HFpEF is characterized by the presence of different comorbidities such as type-2 diabetes mellitus (T2DM), visceral obesity and ageing, all contributing to systemic metabolic inflammation [7, 8]
J., Zahir, N., Johnson, K